HK Stock Market Move | CARSGEN-B (02171) rises over 4% as its universal CAR-T products are consecutively approved, and Kaili Meina is included in million-dollar medical insurance.

CARSGEN-B (02171) rose over 4%, with a current increase of 4.43%, priced at HKD 15.8, and a trading volume of HKD 26.6335 million. On the news front, Kehui Pharmaceutical's universal CAR-T therapies have received consecutive approvals. On August 4, the BCMA-targeted universal CAR-T product CT0596 obtained clinical trial approval from the National Medical Products Administration for the treatment of relapsed/refractory multiple myeloma. On August 7, the CD19/CD20 dual-targeted universal CAR-T product CT1190B was once again approved for the treatment of relapsed/refractory large B-cell lymphoma after at least second-line standard therapy failure. It is noteworthy that Kehui Pharmaceutical's first CAR-T cell therapy product for solid tumors, Kairimei, is expected to be launched in June 2026. Following its launch, Kairimei has achieved continuous breakthroughs in commercial insurance accessibility. Previously, Kairimei was included in the designated drug and medical device list of the 2026 flagship edition of the Good Insurance Long-term Medical Insurance, which officially took effect on July 3; on July 22, the companys collaboration with Zhong'an Insurance was established.